Srivastava Sapna
SEC-identified person · CIK 1569226 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Nuvalent, Inc. NUVL | Director | filed 2021–2026 |
| Aura Biosciences, Inc. AURA | Director | filed 2021–2026 |
| Tourmaline Bio, Inc. TRML | Director | filed 2021–2025 |
| Alumis INC. NASDAQ | Director | filed 2024–2025 |
| Theravance INC thrx | Director | filed 2023–2024 |
| SQZ Biotechnologies Co SQZ | Director | filed 2020–2023 |
| Social Capital Suvretta Holdings Corp. II DNAB | Director | filed 2021–2021 |
| Intellia Therapeutics, Inc. NTLA | Chief Financial & Stategy Offr | filed 2016–2016 |
| Medavail Holdings, Inc. MYOS | Director | filed 2013–2015 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.